Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 9746 | eldelumab |
| Synonyms |
| BMS-936557 | MDX-1100 |
| Comments |
| Eldelumab (BMS-936557 and formerly MDX-1100) is a a fully human monoclonal antibody targeting the chemokine CXCL10 (a.k.a. interferon-γ-inducible protein-10 or IP-10) [1]. It is being investigated for its anti-inflammatory action in autoimmune conditions. BLAST peptide sequence analysis reveals exact matches with heavy and light chain variable regions claimed in patent US8258266, and identify eldelumab as clone 6A5 [1]. |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 463 |
| Other databases | |
| GtoPdb PubChem SID | 315661132 |
| Search PubMed clinical trials | eldelumab |
| Search PubMed titles | eldelumab |
| Search PubMed titles/abstracts | eldelumab |
